Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/30/2025 | $42.00 | Neutral → Overweight | Cantor Fitzgerald |
| 2/19/2025 | $57.00 → $36.00 | Overweight → Neutral | Cantor Fitzgerald |
| 1/6/2025 | $57.00 | Overweight | Cantor Fitzgerald |
| 9/11/2024 | $41.00 → $36.00 | Overweight → Neutral | Piper Sandler |
| 1/3/2023 | $44.00 → $45.00 | Buy | Jefferies |
| 12/1/2021 | $40.00 → $44.00 | Buy | Jefferies |
144 - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Subject)
144 - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Subject)
144 - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Subject)
Postpartum depression is a leading cause of maternal mortality in Europe1-2, and is one of the most common medical conditions associated with pregnancy3-5; up to 20% of women experience postpartum depressive symptoms6-11The approval of this new therapeutic approach introduces an oral, 14-day treatment specifically indicated for PPDThe EC approval of ZURZUVAE is based on the SKYLARK study, which demonstrated rapid relief from depressive symptoms as early as day 3 and sustained through day 45 compared to placebo CAMBRIDGE, Mass., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) announced that the European Commission (EC) has granted marketing authorization for ZURZUVAE® (zurano
ROCKVILLE, Md., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today management will participate in the following September investor conferences: Cantor Global Healthcare ConferenceDate:Fireside chat:Place: Wednesday, September 3, 2025 8:00 a.m. ET New York Marriott Marquis, New York, NY Wells Fargo Healthcare ConferenceDate:Fireside chat:Place: Thursday, September 4, 2025 8:45 a.m. ET Encore Boston Harbor, Everett, MA TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit (Virtual)Da
Net sales of Qelbree® increased 31% in the second quarter of 2025, compared to the same period in 2024. Net sales of Qelbree of $77.6 million and $142.3 million in the second quarter and first six months of 2025, respectively. Net sales of GOCOVRI® increased 16% in the second quarter of 2025, compared to the same period in 2024. Net sales of GOCOVRI of $36.7 million and $67.4 million in the second quarter and first six months of 2025, respectively. ONAPGO™ (apomorphine hydrochloride) launched in April 2025.Total revenues were $165.5 million and $315.3 million for the three and six months ended June 30, 2025, respectively, compared to $168.3 million and $312.0 million, respectively, for the s
Cantor Fitzgerald upgraded Supernus Pharma from Neutral to Overweight and set a new price target of $42.00
Cantor Fitzgerald downgraded Supernus Pharma from Overweight to Neutral and set a new price target of $36.00 from $57.00 previously
Cantor Fitzgerald initiated coverage of Supernus Pharma with a rating of Overweight and set a new price target of $57.00
4 - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Issuer)
4 - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Issuer)
4 - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Issuer)
Net sales of Qelbree® increased 31% in the second quarter of 2025, compared to the same period in 2024. Net sales of Qelbree of $77.6 million and $142.3 million in the second quarter and first six months of 2025, respectively. Net sales of GOCOVRI® increased 16% in the second quarter of 2025, compared to the same period in 2024. Net sales of GOCOVRI of $36.7 million and $67.4 million in the second quarter and first six months of 2025, respectively. ONAPGO™ (apomorphine hydrochloride) launched in April 2025.Total revenues were $165.5 million and $315.3 million for the three and six months ended June 30, 2025, respectively, compared to $168.3 million and $312.0 million, respectively, for the s
ROCKVILLE, Md., July 31, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) ("Supernus") today announced that it has successfully completed its previously announced acquisition of Sage Therapeutics, Inc. (NASDAQ:SAGE) ("Sage"). "Sage is an ideal fit in our corporate development strategy, adding a significant fourth growth product to our portfolio and further diversifying our sources of future revenue," said Jack Khattar, President and CEO of Supernus Pharmaceuticals. "With our proven track record of strong commercial execution along with the expected cost synergies, the acquisition is expected to be accretive in 2026." Compelling Strategic Rationale Strengthens psychi
ROCKVILLE, Md., July 22, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the second quarter of 2025 after the market closes on Tuesday, August 5, 2025. Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a conference call to present the second quarter 2025 financial and business results on Tuesday, August 5, 2025 at 4:30 p.m. ET. Following management's prepared remarks and discussion of business results, the ca
SC 13G/A - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Subject)
SC 13G/A - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Subject)
SC 13G - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Subject)
Jay is sharing his story of receiving an ADHD diagnosis and eventually finding his treatment approach with Qelbree15.7 million U.S. children, teens and adults estimated to have been diagnosed with ADHD1,2 ROCKVILLE, Md., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Television personality and sports reporter Jay Glazer is opening up about his personal experiences with attention-deficit/hyperactivity disorder (ADHD) – one of the most common psychiatric diagnoses affecting approximately 10 million adults in the U.S. – and with Qelbree (viloxazine extended-release capsules), a nonstimulant medication for the treatment of ADHD.3 Glazer, who has always been outspoken about his mental health struggles, wa